ICUD-EAU international consultation on bladder cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder

European Urology

Volumn 63, Issue 1, 2013, Pages 36-44

  Burger, Maximilian ^a   Oosterlinck, Willem ^b   Konety, Badrinath ^c   Chang, Sam ^d   Gudjonsson, Sigurdur ^e   Pruthi, Raj ^f   Soloway, Mark ^g   Solsona, Eduardo ^h   Sved, Paul ⁱ   Babjuk, Marko ^j   Brausi, Maurizio A ^k   Cheng, Christopher ^l   Comperat, Eva ^m   Dinney, Colin ⁿ   Otto, Wolfgang ^o   Shah, Jay ⁿ   Thürof, Joachim ^p   Witjes, J Alfred ^q  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF MINNESOTA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^k AUSL Modena   (Italy)

^l SINGAPORE GENERAL HOSPITAL   (Singapore)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o UNIVERSITY OF REGENSBURG   (Germany)

^p JOHANNES GUTENBERG UNIVERSITY   (Germany)

^q RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Bacillus Calmette Gu rin (BCG); Bladder cancer; Cystoscopy; Diagnosis; Guidelines; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR)

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; GEMCITABINE; MITOMYCIN C; VALRUBICIN;

BLADDER BIOPSY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CONSENSUS; CONSULTATION; CYSTECTOMY; CYSTOSCOPY; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; LOW DRUG DOSE; META ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINE CYTOLOGY;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA IN SITU; CYSTECTOMY; DISEASE PROGRESSION; HUMANS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84870477356     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.061     Document Type: Review

References (50)

1. M.S. Soloway It is time to abandon the "superficial" in bladder cancer Eur Urol 52 2007 1564 1565
2. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine - levels of evidence. March 2009. Centre for Evidence-based Medicine Web site. http://www.cebm.net/index.aspx?o=1025.
3. M.B. Amin, J.K. McKenney, and G.P. Paner ICUD-EAU International Consultation on Bladder Cancer 2012: pathology Eur Urol 63 2013 16 35
4. D. Pan, and M.S. Soloway The importance of transurethral resection in managing patients with urothelial cancer in the bladder: proposal for a transurethral resection of bladder tumor checklist Eur Urol 61 2012 1199 1203
5. I. Kausch, M. Sommerauer, and F. Montorsi Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies Eur Urol 57 2010 595 606
6. H.B. Grossman, A. Stenzl, and Y. Fradet Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy J Urol 188 2012 58 62
7. J.A. Witjes, J.P. Redorta, and D. Jacqmin Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations Eur Urol 57 2010 607 614
8. H.W. Herr, and S.M. Donat Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy BJU Int 107 2011 396 398
9. R.J. Sylvester, A. van der Meijden, and J.A. Witjes High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 Suppl 1 2005 90 107
10. D. Tilki, M. Burger, and G. Dalbagni Urine markers for detection and surveillance of non-muscle-invasive bladder cancer Eur Urol 60 2011 484 492
11. A.M. Kamat, P.K. Hegarty, and J.R. Gee ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers Eur Urol 63 2013 4 15
12. M.S. Soloway, and M. Arianayagam Point: routine use of postoperative intravesical chemotherapy after TURBT - should it be done? Urology 76 2010 794 796
13. M.S. Soloway Rationale for intensive intravesical chemotherapy for superficial bladder cancer J Urol 123 1980 461 466
14. R.J. Sylvester, W. Oosterlinck, and A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190 quiz 2435
15. C. De Nunzio, A. Carbone, and S. Albisinni Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial World J Urol 29 2011 517 521
16. S. Gudjonsson, L. Adell, and F. Merdasa Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? the results of a prospective randomised multicentre study Eur Urol 55 2009 773 780
17. A. Bohle, H. Leyh, and C. Frei Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study Eur Urol 56 2009 495 503
18. J. Palou, F. Rodriguez-Rubio, and J. Huguet Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor J Urol 174 2005 859 861 discussion 861
19. J.L. Wright, J. Hotaling, and M.P. Porter Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis J Urol 181 2009 1035 1039 discussion 1039
20. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
21. H.W. Herr Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder? BJU Int 88 2001 683 685
22. M.S. Soloway Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder Urol Oncol 24 2006 58 61
23. C. Bouffioux, K.H. Kurth, and A. Bono Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group J Urol 153 1995 934 941
24. J.L. Au, R.A. Badalament, and M.G. Wientjes Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial J Natl Cancer Inst 93 2001 597 604
25. M.D. Shelley, G. Jones, A. Cleves, T.J. Wilt, M.D. Mason, and H.G. Kynaston Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review BJU Int 109 2012 496 505
26. M.D. Shelley, T.J. Wilt, J. Court, B. Coles, H. Kynaston, and M.D. Mason Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials BJU Int 93 2004 485 490
27. P.U. Malmstrom, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
28. G. Sauter, F. Algaba, and M.B. Amin Non-invasive urothelial neoplasias: WHO classification of non invasive papillary urothelial tumors J.N. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn, World Health Organization classification of tumors pathology and genetics: tumors of the urinary system and male genital organs 2004 IARC Press Lyon, France
29. H.W. Herr Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy J Urol 174 2005 2134 2137
30. K.T. Adiyat, D. Katkoori, C.T. Soloway, R. De los Santos, M. Manoharan, and M.S. Soloway "Complete transurethral resection of bladder tumor": are the guidelines being followed? Urology 75 2010 365 367
31. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
32. R. Jarvinen, E. Kaasinen, A. Sankila, E. Rintala FinnBladder Group Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up Eur Urol 56 2009 260 265
33. D. Tilki, O. Reich, and R.S. Svatek Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients J Urol 183 2010 1757 1763
34. R.J. Sylvester, A.P. van der Meijden, J.A. Witjes, and K. Kurth Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials J Urol 174 2005 86 91 discussion 91-2
35. B.P. Schrier, M.P. Hollander, B.W. van Rhijn, L.A. Kiemeney, and J.A. Witjes Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy Eur Urol 45 2004 292 296
36. G. Dalbagni, K. Vora, and M. Kaag Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer Eur Urol 56 2009 903 910
37. B.W. van Rhijn, M. Burger, and Y. Lotan Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy Eur Urol 56 2009 430 442
38. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
39. O. Shahin, G.N. Thalmann, C. Rentsch, L. Mazzucchelli, and U.E. Studer A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival J Urol 169 2003 96 100
40. S. Denzinger, H.-M. Fritsche, W. Otto, A. Blana, W.-F. Wieland, and M. Burger Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53 2008 146 152
41. H.W. Herr, and G. Dalbagni Defining bacillus Calmette-Guerin refractory superficial bladder tumors J Urol 169 2003 1706 1708
42. H.M. Fritsche, M. Burger, and R.S. Svatek Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort Eur Urol 57 2010 300 309
43. B.L. Gallagher, F.N. Joudi, J.L. Maymi, and M.A. O'Donnell Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy Urology 71 2008 297 301
44. G. Di Lorenzo, S. Perdona, and R. Damiano Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial Cancer 116 2010 1893 1900
45. M. Duchek, R. Johansson, and S. Jahnson Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer: a prospective, randomized, Nordic study Eur Urol 57 2010 25 31
46. O. Nativ, J.A. Witjes, and K. Hendricksen Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin J Urol 182 2009 1313 1317
47. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
48. A. Stenzl, N.C. Cowan, and M. De Santis Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
49. S. van den Bosch, and J. Alfred Witjes Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review Eur Urol 60 2011 493 500
50. R.P. Meijer, and B.W. van Rhijn A plea for long-term surveillance in bacillus Calmette-Guerin-treated non-muscle-invasive bladder cancer Eur Urol 61 2012 508 509